OMICmAge

OMICmAge is a DNA-methylation-based biological age clock that incorporates information from the proteome, metabolome, and routine clinical laboratory data into a single blood-derived estimate — without requiring direct measurement of those additional layers at the time of testing. The clock was developed by Chen, Dwaraka, Carreras-Gallo, Higgins-Chen, Lasky-Su and colleagues, published in Nature Aging (2026), building on a bioRxiv preprint from 2023. Its construction begins with EMRAge, a mortality-linked composite derived from 19 clinical laboratory values across approximately 31,000 Mass General Brigham Biobank records; elastic-net regression then models EMRAge from a candidate pool of 396 epigenetic biomarker proxies (EBPs) — methylation-based surrogates for 266 metabolites, 109 proteins, and 21 clinical variables — and retains 40 EBPs (16 protein, 14 metabolite, 10 clinical) alongside 990 CpG (cytosine-phosphate-guanine) sites in the final model, distilling multi-omic information into an output readable from DNA methylation alone. Validation across independent cohorts from TruDiagnostic (n = 14,213) and Generation Scotland (n = 18,672) showed OMICmAge acceleration associated with type-2 diabetes, stroke, cardiovascular disease, COPD, depression, and cancer, and yielded 5- and 10-year mortality AUC values of approximately 0.89 and 0.87 — several percentage points above PCGrimAge or chronological age alone in head-to-head comparisons. OMICmAge is currently a research tool; it has not been cleared by any regulatory authority as a diagnostic, and its relationship to the aging process remains associational.